Jason Harris | Authors


MEDI5752 Plus Chemotherapy Produces Long DOR, But High Dose Comes With High Toxicity

September 11, 2022

Chemotherapy added to 1500 mg of MEDI5752, a PD-1/CTLA-4 bispecific monoclonal antibody, led to a doubling in duration of response compared with pembrolizumab and chemotherapy in patients with treatment-naïve nonsquamous non–small cell lung cancer.